...
search icon
vtvt-img

vTv Therapeutics Inc, Common Stock

VTVT

NAQ

$23.1699

+$0.94

(4.23%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$51.38M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.83K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.81
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$12.12 L
$29.19 H
$23.1699

About vTv Therapeutics Inc, Common Stock

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of postprandial hyperglycemia in cystic fibrosis related diabetes patients, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non- central nervous system penetrant PDE4 inhibitor that has completed Phase 1 trials for the treatment of inflammatory diseases. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2"related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress. It has a license agreement Newsoara Biopharma Co., Ltd. o develop and commercialize phosphodiesterase type 4 inhibitors program, including the compound HPP737. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Group LLC. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameVTVTSectorS&P500
1-Week Return17.79%4.13%7.14%
1-Month Return33.54%-4.48%-0.92%
3-Month Return56.98%-5.78%-8.95%
6-Month Return56.98%-7.23%-5.21%
1-Year Return-17.78%-1.69%7.95%
3-Year Return-15.49%3.23%28.74%
5-Year Return-72.28%38.7%92.67%
10-Year Return-94.68%88.08%161.14%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue6.41M4.00M2.02M9.00K1.02M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":62.44,"profit":true},{"date":"2022-12-31","value":31.46,"profit":true},{"date":"2023-12-31","value":0.14,"profit":true},{"date":"2024-12-31","value":15.86,"profit":true}]
Cost of Revenue11.02M89.00K92.00K13.60M-[{"date":"2020-12-31","value":81.02,"profit":true},{"date":"2021-12-31","value":0.65,"profit":true},{"date":"2022-12-31","value":0.68,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(4.60M)3.92M1.93M(13.60M)1.02M[{"date":"2020-12-31","value":-117.49,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":49.18,"profit":true},{"date":"2023-12-31","value":-347.17,"profit":false},{"date":"2024-12-31","value":25.97,"profit":true}]
Gross Margin(71.73%)97.78%95.44%(151055.56%)100.00%[{"date":"2020-12-31","value":-71.73,"profit":false},{"date":"2021-12-31","value":97.78,"profit":true},{"date":"2022-12-31","value":95.44,"profit":true},{"date":"2023-12-31","value":-151055.56,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses18.27M25.67M24.56M11.91M25.20M[{"date":"2020-12-31","value":71.17,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":95.68,"profit":true},{"date":"2023-12-31","value":46.39,"profit":true},{"date":"2024-12-31","value":98.17,"profit":true}]
Operating Income(11.85M)(21.66M)(22.54M)(25.50M)(24.18M)[{"date":"2020-12-31","value":-1185200000,"profit":false},{"date":"2021-12-31","value":-2166200000,"profit":false},{"date":"2022-12-31","value":-2254000000,"profit":false},{"date":"2023-12-31","value":-2550200000,"profit":false},{"date":"2024-12-31","value":-2418000000,"profit":false}]
Total Non-Operating Income/Expense(1.63M)4.04M(2.00M)60.00K7.38M[{"date":"2020-12-31","value":-22.08,"profit":false},{"date":"2021-12-31","value":54.65,"profit":true},{"date":"2022-12-31","value":-27.04,"profit":false},{"date":"2023-12-31","value":0.81,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(12.80M)(17.62M)(24.87M)(25.97M)(18.36M)[{"date":"2020-12-31","value":-1280200000,"profit":false},{"date":"2021-12-31","value":-1761600000,"profit":false},{"date":"2022-12-31","value":-2487300000,"profit":false},{"date":"2023-12-31","value":-2596600000,"profit":false},{"date":"2024-12-31","value":-1836200000,"profit":false}]
Income Taxes(3.98M)115.00K200.00K(5.72M)100.00K[{"date":"2020-12-31","value":-1987.5,"profit":false},{"date":"2021-12-31","value":57.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-2858,"profit":false},{"date":"2024-12-31","value":50,"profit":true}]
Income After Taxes(8.83M)(17.73M)(25.07M)(20.25M)(18.46M)[{"date":"2020-12-31","value":-882700000,"profit":false},{"date":"2021-12-31","value":-1773100000,"profit":false},{"date":"2022-12-31","value":-2507300000,"profit":false},{"date":"2023-12-31","value":-2025000000,"profit":false},{"date":"2024-12-31","value":-1846200000,"profit":false}]
Income From Continuous Operations(12.80M)(17.73M)(25.07M)(27.61M)(22.70M)[{"date":"2020-12-31","value":-1280200000,"profit":false},{"date":"2021-12-31","value":-1773100000,"profit":false},{"date":"2022-12-31","value":-2507300000,"profit":false},{"date":"2023-12-31","value":-2761500000,"profit":false},{"date":"2024-12-31","value":-2270500000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(8.83M)(17.73M)(25.07M)(20.25M)(18.46M)[{"date":"2020-12-31","value":-882700000,"profit":false},{"date":"2021-12-31","value":-1773100000,"profit":false},{"date":"2022-12-31","value":-2507300000,"profit":false},{"date":"2023-12-31","value":-2025000000,"profit":false},{"date":"2024-12-31","value":-1846200000,"profit":false}]
EPS (Diluted)(0.19)(0.22)(0.25)(5.00)(3.41)[{"date":"2020-12-31","value":-19,"profit":false},{"date":"2021-12-31","value":-22,"profit":false},{"date":"2022-12-31","value":-25,"profit":false},{"date":"2023-12-31","value":-500,"profit":false},{"date":"2024-12-31","value":-341.22,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

VTVT
Cash Ratio 7.07
Current Ratio 7.34

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

VTVT
ROA (LTM) -61.33%
ROE (LTM) -362.13%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

VTVT
Debt Ratio Lower is generally better. Negative is bad. 0.63
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.32

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

VTVT
Trailing PE NM
Forward PE NM
P/S (TTM) 59.51
P/B 4.96
Price/FCF NM
EV/R 23.55
EV/Ebitda NM
PEG NM

FAQs

What is vTv Therapeutics Inc share price today?

vTv Therapeutics Inc (VTVT) share price today is $23.1699

Can Indians buy vTv Therapeutics Inc shares?

Yes, Indians can buy shares of vTv Therapeutics Inc (VTVT) on Vested. To buy vTv Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in VTVT stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of vTv Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of vTv Therapeutics Inc (VTVT) via the Vested app. You can start investing in vTv Therapeutics Inc (VTVT) with a minimum investment of $1.

How to invest in vTv Therapeutics Inc shares from India?

You can invest in shares of vTv Therapeutics Inc (VTVT) via Vested in three simple steps:

  • Click on Sign Up or Invest in VTVT stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in vTv Therapeutics Inc shares
What is vTv Therapeutics Inc 52-week high and low stock price?

The 52-week high price of vTv Therapeutics Inc (VTVT) is $29.19. The 52-week low price of vTv Therapeutics Inc (VTVT) is $12.12.

What is vTv Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of vTv Therapeutics Inc (VTVT) is 4.96

What is the Market Cap of vTv Therapeutics Inc?

The market capitalization of vTv Therapeutics Inc (VTVT) is $51.38M

What is vTv Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of vTv Therapeutics Inc is VTVT

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top